Cover Image
市場調查報告書

致癌基因抑制劑的市場及開發平台分析:2015年

Oncogene Inhibitors Therapy Market & Pipeline Insight 2015

出版商 KuicK Research 商品編碼 327759
出版日期 內容資訊 英文 500 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
致癌基因抑制劑的市場及開發平台分析:2015年 Oncogene Inhibitors Therapy Market & Pipeline Insight 2015
出版日期: 2015年04月03日 內容資訊: 英文 500 Pages
簡介

致癌基因抑制劑的市場正在急速成長,許多產品位於臨床實驗各階段,甚至也有許多已上市產品位於產業生命週期的各階段。大規模患者群與優良技術是維繫這個市場持續成長的重要要因,此外,投入於R&D的大規模投資也對市場成長具有莫大的貢獻。

本報告提供致癌基因抑制劑的市場及開發平台趨勢相關調查,提供您致癌基因抑制劑概要,機制,成長推進因素與課題分析,企業·適應症·不同階段的各種抑制劑之開發平台分析,並彙整主要企業的簡介等資訊。

第1章 簡介:致癌基因抑制劑

第2章 致癌基因抑制劑的機制

第3章 全球致癌基因抑制劑市場概要

  • 目前市場方案
  • 致癌基因抑制劑:臨床實驗平台分析

第4章 全球致癌基因抑制劑的市場動態

  • 有利的市場指標
  • 商業化的課題

第5章 全球致癌基因抑制劑市場:未來展望

第6章 致癌基因蛋白質抑制劑的開發平台:企業·適應症·不同階段

  • 前臨床
  • 延期·中止

第7章 原癌基因蛋白c-bcl-2抑制劑的開發平台:企業·適應症·不同階段

  • 從研究到核准前
  • 已上市藥的臨床性分析
  • 延期·中止

第8章 原癌基因蛋白b-raf抑制劑的開發平台:企業·適應症·不同階段

  • 從研究到第三階段
  • 已上市藥的臨床性分析
  • 延期·中止

第9章 原癌基因蛋白c-kit抑制劑的開發平台:企業·適應症·不同階段

  • 從研究到核准前
  • 已上市藥的臨床性分析
  • 延期·中止

第10章 原癌基因蛋白c-rel抑制劑的開發平台:企業·適應症·不同階段

  • 研究階段

第11章 原癌基因蛋白c-akt抑制劑的開發平台:企業·適應症·不同階段

  • 從前臨床到第三階段
  • 延期·中止

第12章 原癌基因蛋白c-met抑制劑的開發平台:企業·適應症·不同階段

  • 從前臨床到第三階段
  • 已上市藥的臨床性分析
  • 延期·中止

第13章 原癌基因蛋白c-ret抑制劑的開發平台:企業·適應症·不同階段

  • 從前臨床到第三階段
  • 已上市藥的臨床性分析
  • 延期·中止

第14章 原癌基因蛋白c-mdm2抑制劑的開發平台:企業·適應症·不同階段

  • 從前臨床到第一/二階段
  • 延期·中止

第15章 原癌基因蛋白抑制劑的開發平台:企業·適應症·不同階段

  • 前臨床階段

第16章 原癌基因蛋白c-ets抑制劑的開發平台:企業·適應症·不同階段

  • 前臨床階段

第17章 原癌基因蛋白c-fli-1抑制劑的開發平台:企業·適應症·不同階段

  • 前臨床

第18章 原癌基因蛋白sc-pim-1抑制劑的開發平台:企業·適應症·不同階段

  • 從前臨床到第一/二階段
  • 延期·中止

第19章 原癌基因蛋白c-myc抑制劑的開發平台:企業·適應症·不同階段

  • 從前臨床到第一/二階段
  • 已上市藥的臨床性分析

第20章 原癌基因蛋白s-c-raf抑制劑的開發平台:企業·適應症·不同階段

  • 延期·中止

第21章 原癌基因蛋白s-c-myb抑制劑的開發平台:企業·適應症·不同階段

第22章 複數的致癌基因抑制劑的開發平台:企業·適應症·不同階段

  • 從前臨床到已通過核准
  • 已上市藥的臨床性分析
  • 延期·中止

第23章 競爭環境

  • AstraZeneca
  • ArQule Inc
  • Biogen Idec
  • Boehringer Ingelheim
  • Celgene Corporation
  • Constellation Pharmaceutical
  • Epizyme Pharmaceutical
  • Genentech
  • GalaxoSmithKline
  • Incyte Corporation
  • Johnson & Johnson
  • Merck
  • Novartis
  • Onyx pharmaceuticals
  • Pfizer

圖表一覽

目錄

Oncogenomics is an emerging field that involves screening of genes that may be involved in cancer development. Human genome consists of 23 chromosomal pairs, approximately 20,000- 25,000 genes and 3,234.83 Mb genome size. Oncogene addiction is a phenomenon in which cancer could be checked by deactivating single oncogene. Proto-onco genes are main target of investigators because they may convert into oncogenes at any stage of life. Sequence level similarity and identification of genetic factors are expected to shed more light on their working. It will allow the investigators to develop drugs capable of preventing oncogene activation and activity in the body. Development of such therapeutics is a daunting task because human genome is quite big and consists of variety of genes whose function has yet to be determined by investigators.

Oncogene Inhibitor market is a rapidly growing segment with numerous products at different stages of clinical pipeline and marketed products at different phases of industry life cycle. Pharmaceutical companies are trying to provide efficient medical care to patients and generate significant revenues by their sales. Large patient base and superior technology are some important factors responsible for continuous growth of this market segment across the globe. Several competitors are available for wide range of malignancies which further makes it imperative for them to provide both therapeutic and financial benefit to the patients. Due to which large numbers of pharmaceutical companies are expected to improve their products to achieve higher sales.

Significant investments in research and development segment could also be attributed as the main reason behind its growth. As a result, several innovative products are under investigation which would be introduced in market after passing pre described clinical end points and criteria's set by regulatory authorities. Researchers are trying to develop new formulations to have better safety and efficacy profiles along with minimized side effects. Number of oncogene inhibitor for treatment of different malignancies is increasing every year due to which their market shares are expected to increase several folds in coming years. Escalating competition could be considered as one of the biggest driver for oncogene inhibitor therapeutics because this segment has significantly large number of products.

Different oncogene inhibitors have been successfully commercialized by different pharmaceutical companies in past few decades. Oncogenes like c-met and c-myc are one of the most commonly used targets for inhibitors due their involvement in various cancers. This biological phenomenon has given rise to therapeutics which could be commercialized for different cancer categories. In this way, more revenues could be generated and competition could be offered to other cancer therapeutics due to superior therapeutic efficacy. Ras gene was one of the earliest oncogene identified by investigators known to have proto-oncogenic in nature. However, therapeutic for this gene not available in market due to its complex protein structure that is impregnable by oncogenic inhibitors.

" Oncogene Inhibitors Market & Pipeline Insight 2015" Report Highlight:

  • Global Oncogene Inhibitors Market Overview
  • Oncogene Inhibitors Pipeline by Company, Indication & Phase
  • Oncogene Inhibitors Pipeline: 185 Drugs
  • Majority Oncogene Inhibitors in Preclinical Phase: 105 Drugs
  • Proto Oncogene Protein c met Inhibitors Pipeline: 42 Drugs
  • Proto Oncogene Protein c-akt Inhibitors: 39 Drugs
  • Marketed Oncogene Inhibitors: 22 Drugs
  • Marketed Proto-Oncogene Protein c-bcl-2 Inhibitors: 8 Drugs

Table of Contents

1. Introduction to Oncogene Inhibitors

2. Mechanism of Oncogene Inhibitors

3. Global Oncogene Inhibitors Market Overview

  • 3.1 Current Market Scenario
  • 3.2 Oncogene Inhibitors Clinical Pipeline Insight

4. Global Oncogene Inhibitor Market Dynamics

  • 4.1 Favorable Market Parameters
  • 4.2 Commercialization Challenges

5. Global Oncogene Inhibitor Market Future Prospects

6. Oncogene Protein Inhibitors Pipeline by Company, Indication & Phase

  • 6.1 Preclinical
  • 6.2 Suspended & Discontinued

7. Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Company, Indication & Phase

  • 7.1 Research till Preregistration
  • 7.2 Marketed Drug Clinical Insight
  • 7.3 Suspended & Discontinued

8. Proto Oncogene Protein b raf Inhibitors Pipeline by Company, Indication & Phase

  • 8.1 Research till Phase-III
  • 8.2 Marketed Drug Clinical Insight
  • 8.3 Suspended & Discontinued

9. Proto Oncogene Protein c-kit Inhibitors Pipeline by Company, Indication & Phase

  • 9.1 Research till Preregistration
  • 9.2 Marketed Drug Clinical Insight
  • 9.3 Suspended & Discontinued

10. Proto-Oncogene Protein c-rel Inhibitors Pipeline by Company, Indication & Phase

  • 10.1 Research

11. Proto Oncogene Protein c-akt Inhibitors Pipeline by Company, Indication & Phase

  • 11.1 Preclinical till Phase-III
  • 11.2 Suspended & Discontinued

12. Proto Oncogene Protein c met Inhibitors Pipeline by Company, Indication & Phase

12.1 Preclinical till Phase-III 12.2 Marketed Drug Clinical Insight 12.3 Suspended & Discontinued

13. Proto Oncogene Protein c ret Inhibitors Pipeline by Company, Indication & Phase

  • 13.1 Preclinical till Phase-III
  • 13.2 Marketed Drug Clinical Insight
  • 13.3 Suspended & Discontinued

14. Proto-Oncogene Protein c mdm2 Inhibitors Pipeline by Company, Indication & Phase

  • 14.1 Preclinical till Phase-I/II
  • 14.2 Suspended & Discontinued

15. Proto-Oncogene Protein Inhibitors Pipeline by Company, Indication & Phase

  • 15.1 Preclinical

16. Proto-Oncogene-Protein-c-ets Inhibitors Pipeline by Company, Indication & Phase

  • 16.1 Preclinical

17. Proto-Oncogene Protein c-fli-1 Inhibitors Pipeline by Company, Indication & Phase

  • 17.1 Preclinical

18. Proto Oncogene Proteins c pim 1 Inhibitors Pipeline by Company, Indication & Phase

  • 18.1 Preclinical till Phase-I/II
  • 18.2 Suspended & Discontinued

19. Proto Oncogene Protein c-myc Inhibitors Pipeline by Company, Indication & Phase

  • 19.1 Preclinical till Phase-I/II
  • 19.2 Marketed Drug Clinical Insight

20. Proto Oncogene Proteins c raf Inhibitors Pipeline by Company, Indication & Phase

  • 20.1 Suspended & Discontinued

21. Proto Oncogene Proteins c myb Inhibitors Pipeline by Company, Indication & Phase

22. Multiple Oncogene Inhibitors Pipeline by Company, Indication & Phase

  • 22.1 Preclinical till Registered
  • 22.2 Marketed Drug Clinical Insight
  • 22.3 Suspended & Discontinued

23. Competitive Landscape

  • 23.1 AstraZeneca
  • 23.2 ArQule Inc
  • 23.3 Biogen Idec
  • 23.4 Boehringer Ingelheim
  • 23.5 Celgene Corporation
  • 23.6 Constellation Pharmaceutical
  • 23.7 Epizyme Pharmaceutical
  • 23.8 Genentech
  • 23.9 GalaxoSmithKline
  • 23.10 Incyte Corporation
  • 23.11 Johnson & Johnson
  • 23.12 Merck
  • 23.13 Novartis
  • 23.14 Onyx pharmaceuticals
  • 23.15 Pfizer

List of Figures and Tables

  • Figure 1-1: Features of Oncogenes
  • Figure 1-2: Types of Genes
  • Figure 1-3:Factors Responsible for Conversion of Proto-Oncogenes to Oncogenes
  • Figure 2-1: Activation of Proto-Oncogenes to Oncogenes
  • Figure 2-2:Benefits of Oncogene Inhibitors
  • Figure 2-3: Mechanism of Crizotinib
  • Figure 2-4: Mechanism of Vemurafenib
  • Figure 2-5: Mechanism of Vorinostat
  • Figure 3-1: Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-2: Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-3: Discontinued Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-4: Discontinued Proto-Oncogene Protein c-bcl-2 Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-5: Proto Oncogene Protein b raf Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-6: Proto Oncogene Protein b raf Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-7: Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-8: Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-9: Discontinued Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-10: Discontinued Proto Oncogene Protein c-kit Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-11: Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-12: Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-13: Discontinued Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-14: Discontinued Proto Oncogene Protein c-akt Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-15: Proto Oncogene Protein c met Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-16: Proto Oncogene Protein c met Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-17: Discontinued Proto Oncogene Protein c met Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-18: Discontinued Proto Oncogene Protein c met Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-19: Proto Oncogene Protein c ret Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-20: Proto Oncogene Protein c ret Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-21: Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-22: Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-23: Discontinued Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-24: Discontinued Proto -Oncogene Protein c mdm2 Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-25: Proto Oncogene Protein c pim 1 Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-26: Proto Oncogene Protein c pim 1 Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-27: Proto Oncogene Protein c-myc Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-28: Proto Oncogene Protein c-myc Inhibitors Pipeline by Phase(Number), 2015
  • Figure 3-29: Multiple Oncogene Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-30: Multiple Oncogene Inhibitors Pipeline by Phase(number), 2015
  • Figure 3-31: Discontinued Multiple Oncogene Inhibitors Pipeline by Phase(%), 2015
  • Figure 3-32: : Discontinued Multiple Oncogene Inhibitors Pipeline by Phase(Number), 2015
  • Figure 4-1: Oncogene Inhibitor Market Favorable Parameters
  • Figure 4-2: Commercialization Challenges to Oncogene Inhibitors
Back to Top